---
title: How I approach the treatment of thrombotic complications in patients with myeloproliferative
  neoplasms
date: '2024-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39541574/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241115181608&v=2.18.0.post9+e462414
source: Blood
description: Arterial and venous thromboses are the most significant complications
  in patients with myeloproliferative neoplasms (MPN), with the primary treatment
  goal being thrombotic risk reduction. In MPN with no history of thrombosis, primary
  prevention mainly involves the use of aspirin and cytoreduction is added in high-risk
  patients. However, thrombotic complications can unveil an MPN in approximately 20%
  of cases, necessitating the initiation of both antithrombotic therapy for the thrombosis
  ...
disable_comments: true
---
Arterial and venous thromboses are the most significant complications in patients with myeloproliferative neoplasms (MPN), with the primary treatment goal being thrombotic risk reduction. In MPN with no history of thrombosis, primary prevention mainly involves the use of aspirin and cytoreduction is added in high-risk patients. However, thrombotic complications can unveil an MPN in approximately 20% of cases, necessitating the initiation of both antithrombotic therapy for the thrombosis ...